Patient Education Guide

Wegovy Pill Results: What Weight Loss Can You Expect?

Wegovy pill results vary from person to person. In OASIS 4, adults taking oral semaglutide 25mg lost an average of 13.6% of their starting weight at 64 weeks, compared with 2.2% with placebo. Both groups received diet and activity support. A separate analysis assuming continued treatment estimated 16.6% weight loss. These averages help explain the evidence; they cannot predict your own result or a monthly weight-loss target.

13.6%Average weight loss at 64 weeks
25mg tablet, OASIS 4 overall analysis

16.6%Estimated loss if treatment continued
25mg tablet, OASIS 4 at 64 weeks

76.3%Lost at least 5% of starting weight
25mg tablet at 64 weeks, UK prescribing data

Content last updated: 1 October 2026

Clinical evidence

1. What Do the Wegovy Pill Results Show?

OASIS 4 studied 307 adults without diabetes who had obesity, or overweight with a weight-related condition. Participants received daily oral semaglutide, increased to 25mg, or placebo alongside lifestyle support. The main weight-loss assessment was at 64 weeks.

OASIS 4 outcome at 64 weeks	25mg oral semaglutide	Placebo
Average weight loss: overall analysis	13.6%	2.2%
Average loss: estimated with continued treatment	16.6%	2.8%
Lost at least 5% of starting weight	76.3%	30.5%
Lost at least 10%	59.8%	14.1%
Lost at least 15%	47.0%	5.4%
Lost at least 20%	27.5%	3.0%

Figures above follow the analyses reported in the UK Wegovy tablet prescribing information, section 5.1. Percentage thresholds describe how many participants reached a result, rather than the amount everyone lost.

Why 13.6% and 16.6% are differentThe overall analysis includes the effects of people stopping treatment or using additional weight-loss treatments. The other analysis estimates what would happen if participants continued their assigned treatment without additional weight-loss therapy. Neither figure is a guaranteed personal outcome.

What about the 15.1% figure from OASIS 1?

OASIS 1 tested a different dose: 50mg daily for 68 weeks. Average weight loss was 15.1%, compared with 2.4% with placebo. That study provides supporting evidence for oral semaglutide, but its dose and results should not be substituted for the licensed 25mg tablet evidence.

Understanding the timeline

2. Wegovy Pill Results Month by Month

There is no reliable kilogram target for each month. The first stages focus on building the dose gradually and checking tolerability. A 64-week trial average cannot be divided into equal monthly losses, and reaching the maintenance dose does not mean you should already have reached the trial result.

Starting dose1.5mg dailyAt least one month before considering an increase.

Next stage4mg dailyAt least one month; follow your prescribed plan.

Next stage9mg dailyAt least one month; tolerability affects progression.

Maintenance25mg dailyThe recommended maintenance dose, if appropriate for you.

Your prescriber may keep you on a previous dose when needed. See the Wegovy pill dosage guide for the full schedule; do not speed up treatment to chase a result.

Stage	What to track	What it does not mean
Early treatment	Your prescribed dose, tolerability and weight trend	A small early change does not predict your final result.
After dose increases	Whether you can follow the routine and manage side effects	A higher dose does not guarantee a set amount of loss.
Ongoing treatment	Progress, health goals and whether treatment remains suitable	Weight loss does not have to continue at the same rate each month.

If your weight loss slows or stops

A plateau is a reason to review your progress, not to increase the dose yourself. Speak to your prescriber about your routine, symptoms and treatment plan. Further weight loss is not guaranteed.

Putting percentages in context

3. What Does 13.6% Weight Loss Mean in Kilograms?

The same percentage translates into different amounts at different starting weights. The examples below apply the OASIS 4 overall average to three starting weights, rounded to one decimal place. They do not show what a person at that weight should expect to lose.

Illustration: starting weight 90kg

Calculation: 90 × 13.6%

Based on the 64-week trial average

12.2kg lossCalculated remaining weight: 77.8kg. This is an arithmetic example, not a patient case or forecast.

Illustration: starting weight 110kg

Calculation: 110 × 13.6%

Based on the 64-week trial average

15.0kg lossCalculated remaining weight: 95.0kg. This is an arithmetic example, not a patient case or forecast.

Illustration: starting weight 130kg

Calculation: 130 × 13.6%

Based on the 64-week trial average

17.7kg lossCalculated remaining weight: 112.3kg. This is an arithmetic example, not a patient case or forecast.

Your own progress can differSome participants lost more than the average and others less. A starting weight alone is not enough to predict a response or determine treatment suitability.

Looking beyond weight

4. Other Outcomes and the Limits of the Evidence

Weight was not the only outcome measured. OASIS 4 also assessed waist size and physical functioning. These findings should be described separately from claims about preventing disease.

Outcome	What OASIS 4 showed
Waist circumference	Average reduction of 12.2cm with the tablet versus 2.8cm with placebo at 64 weeks, in the UK prescribing information.
Physical functioning	The published trial reported greater improvement with oral semaglutide on a weight-related physical-function score.
What remains uncertain	These results do not establish that the 25mg tablet prevents heart attacks or guarantees better sleep, less joint pain or a particular blood-pressure improvement.

The study excluded people with diabetes, so it should not be presented as a trial of weight-loss results in people with type 2 diabetes. Discuss your own health goals and other conditions with your prescriber.

Reviewing your response

5. What Can Affect Your Wegovy Pill Results?

A useful review looks at how treatment fits into everyday life, as well as your weight trend. Slow progress is not automatically a sign that you have done something wrong.

What to review	Why it matters	Practical next step
Tablet routine	Food, drink and timing can affect absorption.	Check how to take the Wegovy pill and follow the leaflet.
Dose and tolerability	Side effects may affect the treatment plan.	Read about Wegovy pill side effects and tell your prescriber about symptoms.
Diet and activity	The trial included lifestyle support in both groups.	Agree realistic eating and activity changes that suit your health and circumstances.
Progress over time	A trial average cannot predict an individual response.	Bring a record of your weight trend, dose and concerns to your review.

Comparing treatments

6. How Do Wegovy Pill Results Compare with Injections?

Separate studies use different doses, populations, follow-up periods and statistical methods. Placing their headline averages side by side is not a like-for-like test and cannot prove which treatment will work best for you.

Comparison	What to consider	Read more
Wegovy pill and Wegovy injection	Both contain semaglutide, but their doses and administration differ. OASIS 4 compared the pill with placebo, not the injection.	Our Wegovy pill vs injection comparison.
Wegovy pill and Mounjaro	Mounjaro contains tirzepatide. Trial results need context alongside suitability, side effects and the daily or weekly routine.	Our Wegovy pill vs Mounjaro guide.

Your prescriber can help weigh the evidence against your medical history and preferences. The highest headline percentage is not, on its own, a treatment recommendation.

Common questions

Frequently Asked Questions

How much weight can I lose with the Wegovy pill?

OASIS 4 reported average loss of 13.6% at 64 weeks in the overall analysis of the 25mg tablet. The estimate assuming continued treatment was 16.6%. Your own result may be higher or lower.

How quickly will I see Wegovy pill results?

The trial does not provide a guaranteed first-month result. Early treatment includes gradual dose increases, and your response should be reviewed over time with your prescriber.

What if I am not losing weight on the Wegovy pill?

Arrange a review rather than changing the dose yourself. Your prescriber can check your treatment routine, tolerability and progress, and decide whether the plan remains appropriate.

Can I lose more than the trial average?

Yes, an average includes a range of outcomes. In the UK prescribing information, 27.5% of the 25mg tablet group reached at least 20% weight loss at 64 weeks. That does not predict whether you will reach the same threshold.

Will my Wegovy pill results last after stopping?

Do not assume that weight loss will be permanent after stopping. Longer-term evidence and stopping-treatment findings need to be distinguished by formulation. Our guide to Wegovy pill long term effects explains the evidence and planning for maintenance.

Does the Wegovy pill work as well as injections?

OASIS 4 was a placebo-controlled trial, not a direct comparison with an injection. Differences between separate trial averages cannot establish that treatments are equivalent or predict which will suit you best.

Considering the Wegovy Pill?

Explore the treatment details and current options at Happy Pharmacy. A prescriber must assess whether treatment is suitable for you.

View Wegovy pill treatment →

Sources: UK Wegovy tablets Summary of Product Characteristics; Wharton et al., OASIS 4, NEJM (2025); Knop et al., OASIS 1, Lancet (2023). Checked 1 October 2026. General information, not personalised medical advice. Calculated examples are illustrative only.